Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
Category: #healthcare  By Akshay Kedari  Date: 2020-01-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer

Survival rate for stage II colon cancer is about 58 to 88% and patients will gain from additional treatments

Guardant Health, Inc., a renowned precision oncology firm, along with NRG Oncology, a National Clinical Trials Network group that conducts both translational and clinical research, have commenced the NRG-GI005 trial for clinical utility validation of the molecular residual disease (MRD) assay of Guardant Health as a diagnostic biomarker to select which patient suffering from stage II colon required an adjuvant chemotherapy.

Apparently, the Circulating TumOr DNA (ctDNA) as a Predictive Biomarker in Stage II Colon Cancer’s Adjuvant Chemotherapy, also called the NRG-GI005 COBRA study, is essentially a multi-center randomized trial that will be enrolling about 1,408 patients suffering from resected stage II colon cancer and will be able to meet the active surveillance as per the physician’s criteria. The patients shall be randomized to be either receiving standard of care active surveillance or therapy based on ctDNA.

Seemingly, the survival rate for stage II colon cancer is about 58 to 88% and indicates that patients will gain from additional treatments. 

The main endpoint of the study is to assess non recurrent survival in patients suffering from ctDNA post-operation as well as treated with chemotherapy in comparison with the existing standard-of-care surveillance. 

Principal Study Investigator and Assistant Professor at Anderson Cancer Center, Van Morris, MD, stated that there is a lack of tools that could predict the success or unsuccessful treatment of stage II colon cancer in patients by surgery alone. If the study proves to be successful, it will authenticate MRD’s clinical utility as a biomarker in identifying patients who can gain from the adjuvant chemotherapy.

Morris further added that the company is looking forward to working with Guardant Health as well as using the company’s LUNAR-1 assay for the given study. The company chose Guardant due to its performance of the assay that incorporates both the methylation profiling and gene mutations and has successfully secured an affirmative predictive value for 100 percent recurrence in recent study.

 

Source Credit- http://investors.guardanthealth.com/news-releases/news-release-details/guardant-health-and-nrg-oncology-initiate-randomized-trial

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Regorafenib/TAS-102 gives clinically meaningful DCR in Metastatic CRC
Regorafenib/TAS-102 gives clinically meaningful DCR in Metastatic CRC
By Akshay Kedari

The data from the REMETY phase 1 dose escalation trial, unveiled at the Gastrointestinal Cancers Sym...

Google on-board with EU’s proposed temporary facial recognition ban
Google on-board with EU’s proposed temporary facial recognition ban
By Akshay Kedari

Technology giants Google and Microsoft have reportedly taken opposing stances as the temporary five-...

Flair Airlines amid plans to grow its fleet and offer low cost fares
Flair Airlines amid plans to grow its fleet and offer low cost fares
By Akshay Kedari

Flair Airlines, a scheduled, independent, and low fare airline company, is seeking to expand its fle...